Tech Company Financing Transactions

Ultragenyx Pharmaceutical Funding Round

On 6/20/2011, Ultragenyx Pharmaceutical raised $45 million in Series A funding from F-Prime Capital, TPG Biotech and Healthcap Venture Capital.

Transaction Overview

Company Information

Company Status

Publicly-held

Industry

Biopharmaceutical

Mailing Address

60 Leveroni Ct.
Novato, CA 94949
USA

Phone

(415) 884-2800

Website

www.ultragenyx.com

Email Address

[email protected]

Overview

Ultragenyx (NASDAQ: RARE) is focused on developing therapeutics for rare diseases. The company will build on management's experience in choosing and developing products with clear mechanisms of action in untreated rare diseases.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Emil Kakkis

        

Chief Financial Officer

Shalini Sharp

        

Chief Operating Officer

John Pinion

        

VP - Bus. Development

Thomas Kassberg

        

Browse more venture capital transactions:

Prev: 6/20/2011: iControl Networks venture capital transaction
Next: 6/20/2011: Apellis Pharmaceuticals venture capital transaction

Share this article

Where The Data Comes From

We do our best to record all VC transactions involving tech companies. VC investment data records reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary